Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

Clicks: 393
ID: 114510
1998
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Antiviral chemotherapy with famciclovir results in clinically and statistically significant reductions in the symptoms associated with HSV infection and the symptomatic and asymptomatic shedding of HSV among HIV-positive persons.
Reference Key
t1998annalsfamciclovir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Schacker T;Hu HL;Koelle DM;Zeh J;Saltzman R;Boon R;Shaughnessy M;Barnum G;Corey L;;
Journal annals of internal medicine
Year 1998
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9424977
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't u.s. gov't adult female male aged middle aged P.H.S. regression analysis Clinical Trial Randomized Controlled Trial Antibodies Double-Blind Method Proportional Hazards Models viral / blood l corey antiviral agents / therapeutic use* cd4 lymphocyte count cross-over studies virus activation virus shedding aids-related opportunistic infections / drug therapy* pmid:9424977 doi:10.7326/0003-4819-128-1-199801010-00004 t schacker h l hu 2-aminopurine / analogs & derivatives* 2-aminopurine / therapeutic use aids-related opportunistic infections / virology famciclovir herpes simplex / drug therapy* herpes simplex / virology simplexvirus / growth & development

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.